Red Light Holland - Director and CEO, Todd Shapiro (Right).
Director and CEO, Todd Shapiro (Right).
Source: Daily Hive.
  • Red Light Holland (TRIP) has started growing its second crop of approximately 1 million grams of magic truffles
  • The truffles consist of three different strains, including Psilocybe Mexicana, Psilocybe Galindoi and Psilocybe Tampanensis
  • Red Light Holland’s growth operation, production and distribution facility is in Horst, The Netherlands
  • The batch is expected to be available in The Netherlands by mid-2021
  • Red Light Holland is up 1.11  per cent at C$0.45 per share

Red Light Holland (TRIP) has started growing its second crop of approximately 1 million grams of magic truffles.

The truffles consist of three different strains, including Psilocybe Mexicana, Psilocybe Galindoi and Psilocybe Tampanensis.

Red Light Holland is an Ontario-based company focused on the production, growth and sale of magic truffles to the legal market within The Netherlands.

Red Light Holland CEO and Director Todd Shapiro said this batch is expected to be 10 times the size of the original batch.

“We are proud as a company, in the Psychedelic sector to actually produce product now, as opposed to making mere projections about the future. We believe in providing responsible adult access now, through education and information and we are happy to be moving so quickly and efficiently,” he added.

Shapiro said Red Light Holland is almost done harvesting its first batch which has been pre-sold. Red Light Holland’s growth operation, production and distribution facility is in Horst, The Netherlands.

The expected batch is expected to be available in The Netherlands by mid-2021.

Red Light Holland is up 1.11 per cent at C$0.45 per share.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.